Technology

Aeglea BioTherapeutics

$7.89
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.09 (-1.13%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell AGLE and other stocks, options, and ETFs commission-free!

About AGLE

Aeglea Biotherapeutics, Inc. operates as a clinical-stage biotechnology company, which develops next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe in December 2013 and is headquartered in Austin, TX. The listed name for AGLE is Aeglea BioTherapeutics, Inc. Common Stock.

CEO
Anthony G. Quinn
Employees
76
Headquarters
Austin, Texas
Founded
2013
Market Cap
378.22M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
206.07K
High Today
$8.15
Low Today
$7.81
Open Price
$8.07
Volume
237.77K
52 Week High
$11.38
52 Week Low
$3.50

Collections

AGLE Earnings

-$0.68
-$0.45
-$0.23
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Feb 24, Pre-Market

You May Also Like

AGNCM
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure